Literature DB >> 10765141

Introduction to antibody engineering and phage display.

N A Watkins1, W H Ouwehand.   

Abstract

The vertebrate immune system, capable of rapidly producing highly specific antibodies upon immunisation, has been used to produce murine monoclonal antibodies (mAbs) via immortalisation and isolation of antibody-secreting cells. These mAbs have had a profound impact in the fields of diagnostics and therapeutics. However, the therapeutic use of murine mAbs is complicated by their immunogenicity. To circumvent this immunogenicity, antibody engineering techniques which render murine mAbs more compatible with the human immune system have been devised. Over the last decade, the technique of antibody phage display, which facilitates the production of human mAbs, has been developed. This review serves as an introduction to antibody engineering, phage display and the development of antibody fragments into viable diagnostic and therapeutic reagents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765141     DOI: 10.1159/000031154

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  11 in total

1.  Preparation of single chain variable fragment of MG(7) mAb by phage display technology.

Authors:  Z C Yu; J Ding; Y Z Nie; D M Fan; X Y Zhang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 3.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

4.  Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.

Authors:  Farideh Hosseinzadeh; Saeed Mohammadi; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2017-10

5.  Characterization of the inhibition mechanism of a tissuefactor inhibiting single-chain variable fragment: a combined computational approach.

Authors:  Jan-G Vermeulen; Felicity Burt; Esta van Heerden; Louis Lategan du Preez; Muriel Meiring
Journal:  J Mol Model       Date:  2020-03-26       Impact factor: 1.810

6.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.

Authors:  Roberto Ronca; Patrizia Benzoni; Angela De Luca; Elisabetta Crescini; Patrizia Dell'Era
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

Review 8.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

9.  Antibody-Based Protective Immunity against Helminth Infections: Antibody Phage Display Derived Antibodies against BmR1 Antigen.

Authors:  Anizah Rahumatullah; Izzati Zahidah Abdul Karim; Rahmah Noordin; Theam Soon Lim
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

Review 10.  Therapeutic applications of monoclonal antibodies.

Authors:  Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal:  Am J Med Sci       Date:  2002-07       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.